ArticleInternational journal of molecular sciences2025

Onvansertib-Based Second-Line Therapies in Combination with Gemcitabine and Carboplatin in Patient-Derived Platinum-Resistant Ovarian Carcinomas.

Federica Guffanti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.